DelveInsight’s “Gastroparesis Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of Gastroparesis, historical and forecasted epidemiology, as well as the Gastroparesis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Gastroparesis Market with DelveInsight’s In-Depth Report @ Gastroparesis Market Size
Key Takeaways from the Gastroparesis Market Report
- In April 2026, Dr. Falk Pharma GmbH and Renexxion Ireland announced that data from the Global Phase IIb (MOVE-IT) study of naronapride in 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis had been selected for a late-breaking oral presentation at DDW 2026 in the US.
- In March 2026, CinDome Pharma announced that enrollment in the Phase II (envisionGI) trial of deudomperidone (CIN-102) for adults with idiopathic gastroparesis had been completed.
- In September 2025, CinDome Pharma announced that it had completed enrollment in the (envision3D) Phase II clinical trial of deudomperidone in adults with diabetic gastroparesis.
- In June 2025, Processa Pharmaceuticals announced that it had entered into a binding term sheet with Intact Therapeutics, granting Intact an exclusive option to license PCS12852, a best-in-class 5-HT4 receptor agonist with the potential to become a first meaningful treatment for gastroparesis and other gastrointestinal motility disorders.
- According to DelveInsight’s estimates, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of gastroparesis with ~724,000 cases in 2025.
- As per NORD, gastroparesis demonstrates a gender bias affecting more women than men, with approximately 80% of idiopathic cases being women. Among diagnosed patients, ~70% are females while only ~30% are males.
- In the US, the highest etiology-specific cases accounted for diabetes (57%), followed by postsurgical cases (15%) and drug-induced cases (11%) in 2025.
- Gastroparesis cases categorized by severity show that in the US, mild cases represent the largest share at 43%, followed by severe cases.
- In the US in 2025, the highest age-specific cases were seen in the 65+ age group, followed by those aged 48–57, while the lowest were in the 18–27 age group.
- The leading Gastroparesis companies such as Evoke Pharma , Renexxion Ireland Ltd , CinDome Pharma, Neurogastrx, Inc. , Processa Pharmaceuticals , Intact Therapeutics , and others.
- Promising Gastroparesis Therapies such as Naronapride (ATI-7505), CIN-102 (deudomperidone), NG101 (metopimazine), PCS12852 (YH12852), and others.
Stay ahead in the Gastroparesis Therapeutics Market with DelveInsight’s Strategic Report @ Gastroparesis Market Outlook
Gastroparesis Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases of Gastroparesis
- Etiology-specific Cases of Gastroparesis
- Gender-specific Diagnosed Prevalent Cases of Gastroparesis
- Age-specific Diagnosed Prevalent Cases of Gastroparesis
- Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying
- Treated Cases of Gastroparesis
Download the report to understand which factors are driving Gastroparesis epidemiology trends @ Gastroparesis Prevalence
Gastroparesis Pipeline Analysis
• Naronapride (ATI-7505): Renexxion
Naronapride is an investigational gastrointestinal prokinetic drug designed to treat disorders of gut motility, including gastroparesis. Naronapride works through a differentiated dual mechanism of action—5-HT4 receptor agonism and dopamine D2 receptor antagonism. Its dual mechanism of action, minimal systemic bioavailability, and differentiated pharmaceutical and pharmacokinetic profile are designed to deliver targeted activity within the GI tract while limiting systemic exposure. In October 2021, Renexxion Ireland announced that it had entered into a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH to jointly develop and commercialize Naronapride. In April 2026, data from the Global Phase IIb (MOVE-IT) study of naronapride in 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis were selected for a late-breaking oral presentation at DDW 2026 in the US.
• CIN-102 (deudomperidone): CinDome Pharma
Deudomperidone is an oral, small-molecule dopamine D2/D3 receptor antagonist. As an antiemetic and prokinetic, deudomperidone improves gastric emptying and relieves the symptoms of nausea and vomiting associated with gastroparesis. Deudomperidone has completed its Phase I program, demonstrated a negative thorough QT study, and conducted a proof-of-concept Phase II trial demonstrating a reduction in gastric emptying. In March 2026, CinDome Pharma announced that enrollment in the Phase II (envisionGI) trial of deudomperidone for adults with idiopathic gastroparesis had been completed. Topline safety and efficacy results from EnvisionGI are expected in the second half of 2026.
• NG101 (metopimazine): Neurogastrx
NG101 (metopimazine) is under investigation for its antiemetic action, potentially relieving persistent nausea and vomiting associated with gastroparesis. This dopamine D2/3 receptor antagonist represents another investigational approach to managing gastroparesis symptoms.
• PCS12852 (YH12852): Processa Pharmaceuticals/Intact Therapeutics
PCS12852 is a best-in-class 5-HT4 receptor agonist with the potential to become a first meaningful treatment for gastroparesis and other gastrointestinal motility disorders. In June 2025, Processa Pharmaceuticals announced that it had entered into a binding term sheet with Intact Therapeutics, granting Intact an exclusive option to license PCS12852.
Gastroparesis Drugs Market Insights
Oral metoclopramide has long been the sole US FDA-approved option for diabetic gastroparesis. The current treatment landscape includes dietary modifications as the first line of treatment for gastroparesis, along with medications such as prokinetics and antiemetics, pain management, and surgical options. Several drugs approved for other conditions are utilized off-label to alleviate gastroparesis symptoms, including nortriptyline (a tricyclic antidepressant), mirtazapine, buspirone, and others.
While current treatment options remain limited, ongoing clinical development and innovation in prokinetic and antiemetic therapies are likely to expand the therapeutic landscape. The gastroparesis pipeline is gradually evolving, with investigational agents targeting gastrointestinal motility and symptom control through novel mechanisms. The emergence of safer and more targeted therapies, along with improvements in diagnostic capabilities and increasing disease awareness, is projected to propel steady market growth.
Get In-Depth Knowledge on Gastroparesis Market Trends and Forecasts with DelveInsight @ Gastroparesis Treatment Market
Gastroparesis Companies
Evoke Pharma , Renexxion Ireland Ltd , CinDome Pharma, Neurogastrx, Inc. , Processa Pharmaceuticals , Intact Therapeutics , and others.
Gastroparesis Market Outlook
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying without any mechanical obstruction. It commonly occurs in people with long-standing diabetes but can also arise from post-surgical complications, medications, or idiopathic causes. Diabetic gastroparesis is the most common subtype, followed by postsurgical cases, with most pipeline therapies targeting idiopathic and diabetic forms due to their higher prevalence and commercial potential.
Treatment focuses on symptom management, dietary modifications, and improving gastric motility. The gastroparesis market in the US was valued at approximately USD ~150 million in 2025 and is projected to reach ~970 million by 2036, growing at approximately 18% CAGR during the forecast period (2026–2036). Among the 7MM, the US represents the largest gastroparesis market.
Scope of the Gastroparesis Market Report
- Coverage- 7MM
- Study Period- 2022-2036
- Forecast Period- 2026-2036
- Gastroparesis Companies- Evoke Pharma , Renexxion Ireland Ltd , CinDome Pharma, Neurogastrx, Inc. , Processa Pharmaceuticals , Intact Therapeutics , and others.
- Gastroparesis Therapies- Metoclopramide (GIMOTI), Naronapride (ATI-7505), CIN-102 (deudomperidone), NG101 (metopimazine), PCS12852 (YH12852), and others
- Gastroparesis Market Access & Reimbursements, Unmet Needs and Perspectives
- Gastroparesis SWOT Analysis and KOL Views
Unlock Strategic Insights with DelveInsight’s Comprehensive Gastroparesis Market Report @ Gastroparesis Market Drivers and Barriers
Table of Contents
- Key Insights
- Executive Summary
- Gastroparesis Competitive Intelligence Analysis
- Gastroparesis Market Overview at a Glance
- Gastroparesis Disease Background and Overview
- Gastroparesis Patient Journey
- Gastroparesis Epidemiology and Patient Population
- Gastroparesis Treatment Algorithm, Current Treatment, and Medical Practices
- Gastroparesis Unmet Needs
- Key Endpoints of Gastroparesis Treatment
- Gastroparesis Marketed Products
- Gastroparesis Emerging Therapies
- Gastroparesis Seven Major Market Analysis
- Attribute Analysis
- Gastroparesis Market Outlook (7MM)
- Gastroparesis Access and Reimbursement Overview
- KOL Views on the Gastroparesis Market
- Gastroparesis Market Drivers
- Gastroparesis Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
